CN115916188A - 尼罗司他与bcma定向疗法的组合疗法及其用途 - Google Patents

尼罗司他与bcma定向疗法的组合疗法及其用途 Download PDF

Info

Publication number
CN115916188A
CN115916188A CN202180034598.4A CN202180034598A CN115916188A CN 115916188 A CN115916188 A CN 115916188A CN 202180034598 A CN202180034598 A CN 202180034598A CN 115916188 A CN115916188 A CN 115916188A
Authority
CN
China
Prior art keywords
subject
bcma
nilostat
therapy
dihydrobromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034598.4A
Other languages
English (en)
Chinese (zh)
Inventor
托德·韦伯斯特·希勒
巴德雷丁·伊德里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Springworths Treatment Co ltd
Original Assignee
Springworths Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworths Treatment Co ltd filed Critical Springworths Treatment Co ltd
Publication of CN115916188A publication Critical patent/CN115916188A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
CN202180034598.4A 2020-03-13 2021-03-12 尼罗司他与bcma定向疗法的组合疗法及其用途 Pending CN115916188A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13
US62/989,372 2020-03-13
PCT/US2021/022177 WO2021183934A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Publications (1)

Publication Number Publication Date
CN115916188A true CN115916188A (zh) 2023-04-04

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034598.4A Pending CN115916188A (zh) 2020-03-13 2021-03-12 尼罗司他与bcma定向疗法的组合疗法及其用途

Country Status (17)

Country Link
US (1) US20230121547A1 (https=)
EP (1) EP4132515A1 (https=)
JP (2) JP7781764B2 (https=)
KR (1) KR20230009873A (https=)
CN (1) CN115916188A (https=)
AR (1) AR121566A1 (https=)
AU (1) AU2021236340A1 (https=)
BR (1) BR112022018251A2 (https=)
CA (1) CA3171267A1 (https=)
CL (1) CL2022002479A1 (https=)
CO (1) CO2022014388A2 (https=)
IL (1) IL296075A (https=)
MX (1) MX2022011258A (https=)
PE (1) PE20230614A1 (https=)
TW (1) TW202200132A (https=)
WO (1) WO2021183934A1 (https=)
ZA (1) ZA202209989B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3230245A1 (en) 2021-09-01 2023-03-09 Springworks Therapeutics, Inc. Synthesis of nirogacestat
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
CN118302412A (zh) * 2021-11-23 2024-07-05 梯瓦制药国际有限责任公司 Nirogacestat盐的固态形式
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
EP4678635A1 (en) * 2023-03-09 2026-01-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180214553A1 (en) * 2015-07-24 2018-08-02 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019090364A1 (en) * 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
CN110461335A (zh) * 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US20190367628A1 (en) * 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
US20200055948A1 (en) * 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN112118842A (zh) * 2018-01-17 2020-12-22 明赛制药股份公司 用于癌症治疗的联合疗法
US20210171651A1 (en) * 2017-11-08 2021-06-10 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimmunotherapies
US20220288088A1 (en) * 2018-05-24 2022-09-15 Ayala Pharmaceuticals Inc. Combination of immunotherapeutics and bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149855B2 (en) * 2014-02-05 2018-12-11 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides
CN110622566B (zh) 2017-05-05 2021-04-20 华为技术有限公司 一种辅助数据传输方法、设备及系统
BR112021020409A2 (pt) * 2019-04-10 2021-12-07 Glaxosmithkline Ip Dev Ltd Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase
EP4010322B1 (en) 2019-08-09 2025-11-05 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180214553A1 (en) * 2015-07-24 2018-08-02 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
CN110461335A (zh) * 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) * 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019090364A1 (en) * 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US20210171651A1 (en) * 2017-11-08 2021-06-10 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimmunotherapies
CN112118842A (zh) * 2018-01-17 2020-12-22 明赛制药股份公司 用于癌症治疗的联合疗法
US20220288088A1 (en) * 2018-05-24 2022-09-15 Ayala Pharmaceuticals Inc. Combination of immunotherapeutics and bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer
US20190367628A1 (en) * 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEPHEN EASTMAN, BS, MS: "Synergistic Activity of Belantamab Mafodotin (anti BCMA immuno-conjugate) with PF-03084014 (gamma secretase inhibitor) in Bcma-Expressing Cancer Cell Lines", SYNERGISTIC ACTIVITY OF BELANTAMAB MAFODOTIN (ANTI BCMA IMMUNO-CONJUGATE) WITH PF-03084014 (GAMMA SECRETASE INHIBITOR) IN BCMA-EXPRESSING CANCER CELL LINES, 1 November 2019 (2019-11-01) *

Also Published As

Publication number Publication date
JP2025168430A (ja) 2025-11-07
WO2021183934A1 (en) 2021-09-16
CA3171267A1 (en) 2021-09-16
PE20230614A1 (es) 2023-04-14
MX2022011258A (es) 2023-01-11
TW202200132A (zh) 2022-01-01
JP2023517243A (ja) 2023-04-24
BR112022018251A2 (pt) 2022-11-08
CO2022014388A2 (es) 2023-02-16
CL2022002479A1 (es) 2023-08-18
JP7781764B2 (ja) 2025-12-08
EP4132515A1 (en) 2023-02-15
IL296075A (en) 2022-11-01
AR121566A1 (es) 2022-06-15
ZA202209989B (en) 2025-12-17
AU2021236340A1 (en) 2022-09-29
KR20230009873A (ko) 2023-01-17
US20230121547A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
CN115916188A (zh) 尼罗司他与bcma定向疗法的组合疗法及其用途
TWI620565B (zh) 治療及預防移植物抗宿主病之方法
WO2021061749A1 (en) Combination therapies
BR112018001688B1 (pt) Uso de um composto
HK1251162B (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
JP2022095820A (ja) ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
WO2025044424A1 (zh) 一种基于免疫检查点阻断的抗肿瘤药物组合物及其应用
WO2023104151A1 (zh) 治疗肿瘤的药物组合及用途
ES2978336T3 (es) Combinación de un inhibidor de Mcl-1 y midostaurina, usos y composiciones farmacéuticas de la misma
TW202410898A (zh) Fak抑制劑及egfr-tki的藥物組合及用途
EA051675B1 (ru) Комбинированная терапия с нирогацестатом и bcma-направленной терапией и ее применение
CN115317493A (zh) 一种硼酸类小分子化合物在制备增强免疫检查点抑制剂疗效及治疗白血病药物中的应用
WO2017177515A1 (zh) 4-羟基水杨酰苯胺在制备抗骨髓瘤、淋巴瘤药物中的应用
EP4031129A1 (en) Combination of small molecule inhibitor of the pd-1/pd-l1 interaction and anti-pd-1 antibody for treating cancer
TW201934543A (zh) 以鋅結合劑為基礎的ｅｂｎａ１專一性化合物
RU2295335C2 (ru) Лекарственные препараты, обладающие иммуномодулирующим, противовоспалительным и противоопухолевым свойствами, и способ их получения
CN111195251A (zh) 西达本胺的应用
US20250360124A1 (en) Novel ras inhibitors
WO2015037764A1 (ko) Gpcr19 경로의 활성화에 의한 골수 유래 면역 조절 세포 및 면역 조절 b 림프구의 체내외 증폭
JP7805005B2 (ja) 腫瘍治療の医薬組み合わせとその使用
WO2025153072A1 (en) Therapy for fgfr1 rearrangement-related cancer
US20250375419A1 (en) Novel ras inhibitors
RU2518889C2 (ru) Производное 5-оксипиримидина, обладающее противоопухолевой активностью
US20040247589A1 (en) Anti-tumor activity from reptile serum
EP4676934A1 (en) Porphyrins and their pharmaceutical uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination